GO:0071855 neuropeptide receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071855 neuropeptide receptor binding is a molecular function defined as binding to a neuropeptide receptor.
• Neuropeptide-receptor interactions are governed by kinetic parameters such as association and dissociation rates, which determine signaling duration and specificity.
• Key neuropeptide receptor families include neuropeptide S receptor (NPSR1), neuropeptide B/W receptor 1 (NPBWR1), MRGPRX2, and itch receptor complexes.
• Structural and mutagenesis studies have identified critical residues and variants, such as the I107 variant of NPSR1, that affect binding and receptor activation.
• Dysregulation of neuropeptide receptor binding is implicated in anxiety, allergic itch, cancer, and other disorders.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal interrogation of neuropeptide receptor binding in disease.
Description
Neuropeptide receptor binding (GO:0071855) is a molecular function that describes the binding of a ligand to a neuropeptide receptor. Neuropeptides are small signaling proteins released by neurons and other cells that act on specific G protein-coupled receptors (GPCRs) to modulate diverse physiological processes, including pain, itch, anxiety, and immune responses. The binding event is the first step in receptor activation and determines the specificity and duration of downstream signaling. Understanding the kinetic profile of neuropeptide-receptor interactions is essential for drug discovery and for interpreting how mutations alter receptor function. Recent structural studies of human itch receptor complexes have revealed how neuropeptides and antagonists engage their receptors at the atomic level. Computational and mutagenesis approaches have further mapped the binding pockets of receptors such as neuropeptide B/W receptor 1 and neuropeptide S receptor. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0071855, its mechanisms, key genes, disease relevance, and experimental models.
neuropeptide receptor binding At A Glance
| GO ID | GO:0071855 |
|---|---|
| GO term | neuropeptide receptor binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a neuropeptide receptor. |
| Major function | Mediates the initial recognition event between neuropeptides and their cognate receptors, initiating signal transduction. |
| Related receptors | NPSR1, NPBWR1, MRGPRX2, itch receptor complexes. |
| Kinetic properties | Association and dissociation rates determine signaling duration and drug efficacy. |
| Disease relevance | Anxiety, allergic itch, cancer, and pruritic disorders. |
What Is GO:0071855?
According to the Gene Ontology, GO:0071855 neuropeptide receptor binding is the molecular function of binding to a neuropeptide receptor. This term describes the physical interaction between a ligand (such as a neuropeptide or a synthetic antagonist) and a neuropeptide receptor protein. It does not necessarily imply receptor activation, but it is the prerequisite for downstream signaling. The definition is intentionally broad to encompass binding to any receptor that recognizes neuropeptides, including class A GPCRs like neuropeptide S receptor, neuropeptide B/W receptors, and MRGPRX2.
Why Is neuropeptide receptor binding Important in Cell Biology?
Neuropeptide receptor binding is a central molecular function in neurobiology, immunology, and pharmacology because it gates the actions of neuropeptides on their target cells. The binding kinetics of neuropeptide-receptor interactions can dictate whether a signal is transient or sustained, which has direct implications for drug design and for understanding disease mechanisms. For example, mutations in the neuropeptide S receptor can alter binding affinity and are associated with anxiety-related phenotypes. In allergy and itch, MRGPRX2 binding by neuropeptides or drugs triggers mast cell activation and pruritus, making it a therapeutic target. In cancer, growth hormone-releasing hormone and its receptor binding influence tumor growth, highlighting the broad relevance of this GO term.
• Neuropeptide receptor binding initiates GPCR signaling that regulates neuronal excitability, stress responses, and immune cell activation.
• Kinetic parameters of binding (kon, koff) are critical for predicting drug residence time and efficacy.
• Mutations in neuropeptide receptors, such as NPSR1 I107, can alter binding and receptor activation, linking to anxiety disorders.
• MRGPRX2 binding by neuropeptides and drugs is a key mechanism in pseudo-allergic reactions and chronic itch.
• Structural studies of itch receptor complexes provide templates for designing antagonists with improved binding properties.
• Neuropeptide B/W receptor 1 antagonists are being explored for metabolic and inflammatory conditions.
• Vasopressin receptor binding in the brain is altered in high-anxiety rat models, demonstrating a role in emotional regulation.
• Growth hormone-releasing hormone receptor binding is implicated in cancer progression, offering a target for therapy.
• CRISPR screens can identify genes that modulate neuropeptide receptor binding and downstream signaling.
Molecular Mechanism of neuropeptide receptor binding
Ligand recognition and binding pocket
In simple terms: The neuropeptide fits into a specific pocket on the receptor, like a key in a lock.
Neuropeptide receptors, primarily class A GPCRs, possess a binding pocket formed by transmembrane helices and extracellular loops. Computational docking and mutagenesis studies of neuropeptide B/W receptor 1 have identified key residues that interact with antagonists, revealing the structural basis of ligand recognition. Similarly, mutagenesis of neuropeptide S receptor identified residues critical for binding and led to the development of a suitable peptide tracer for binding studies. Structural determination of human itch receptor complexes has provided high-resolution views of how neuropeptides and small-molecule antagonists occupy the binding pocket.
Binding kinetics and affinity
In simple terms: How fast a neuropeptide attaches to and detaches from its receptor determines how long the signal lasts.
The kinetic profile of neuropeptide-receptor interactions is characterized by association (kon) and dissociation (koff) rate constants, which together define binding affinity (KD) and residence time. These parameters vary widely among neuropeptides and can influence the duration of downstream signaling. For example, slow dissociation can lead to sustained receptor activation, whereas fast dissociation may produce transient effects. Experimental techniques such as radioligand binding and surface plasmon resonance are used to measure these kinetics.
Conformational changes and receptor activation
In simple terms: Once the neuropeptide binds, the receptor changes shape to turn on signaling inside the cell.
Binding of a neuropeptide to its receptor induces conformational changes in the receptor, particularly in transmembrane helix 6, leading to G protein coupling and activation. The I107 variant of human neuropeptide S receptor exhibits altered activation properties, as shown by peptides selectively activating this variant. Structural studies of itch receptor complexes have captured active-state conformations bound to neuropeptides, revealing the molecular rearrangements that occur upon binding.
Regulation by accessory proteins and allosteric modulators
In simple terms: Other proteins and small molecules can change how well the neuropeptide binds to its receptor.
Neuropeptide receptor binding can be modulated by allosteric ligands, receptor dimerization, and interactions with accessory proteins such as arrestins and G proteins. For instance, MRGPRX2 inhibitors like KMH-45 have been developed to block neuropeptide-induced mast cell activation, demonstrating that small molecules can interfere with binding. Additionally, the binding of antagonists to neuropeptide B/W receptor 1 can stabilize inactive conformations, as shown by computational insights.
Pathophysiological alterations in binding
In simple terms: In some diseases, the binding between neuropeptides and their receptors is changed, contributing to symptoms.
Alterations in central neuropeptide expression, release, and receptor binding have been observed in rats bred for high anxiety, with a critical role for vasopressin. In allergology, neuropeptide receptor binding on mast cells and sensory neurons is implicated in itch and inflammation. Growth hormone-releasing hormone and its receptor binding are involved in cancer cell proliferation, suggesting that dysregulated binding can promote tumor growth.
Key Genes Involved in GO:0071855 neuropeptide receptor binding
The following genes encode receptors and ligands that participate in neuropeptide receptor binding (GO:0071855), based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NPSR1 | Neuropeptide S receptor; binds neuropeptide S | I107 variant affects binding and activation; linked to anxiety. |
| NPBWR1 | Neuropeptide B/W receptor 1; binds neuropeptides B and W | Antagonist binding studied computationally; target for metabolic disorders. |
| MRGPRX2 | Mast cell receptor; binds neuropeptides and drugs | Inhibitor KMH-45 blocks binding; target for itch and pseudo-allergy. |
| AVPR1A | Vasopressin receptor 1A; binds vasopressin | Altered binding in high-anxiety rats; role in stress. |
| GHRHR | Growth hormone-releasing hormone receptor | Binding implicated in cancer progression. |
| HRH1 | Histamine receptor H1; binds histamine | Neuropeptide receptor binding in itch and allergy. |
| HRH4 | Histamine receptor H4; binds histamine | Neuropeptide receptor binding in itch and allergy. |
| TACR1 | Tachykinin receptor 1; binds substance P | Neuropeptide receptor binding in inflammation and pain. |
| TACR2 | Tachykinin receptor 2; binds neurokinin A | Neuropeptide receptor binding in smooth muscle contraction. |
| TACR3 | Tachykinin receptor 3; binds neurokinin B | Neuropeptide receptor binding in reproductive function. |
| OPRM1 | Mu-opioid receptor; binds beta-endorphin | Neuropeptide receptor binding in pain and reward. |
| OPRD1 | Delta-opioid receptor; binds enkephalins | Neuropeptide receptor binding in mood and pain. |
| OPRK1 | Kappa-opioid receptor; binds dynorphins | Neuropeptide receptor binding in stress and addiction. |
| NPY1R | Neuropeptide Y receptor Y1 | Neuropeptide receptor binding in feeding and anxiety. |
| NPY2R | Neuropeptide Y receptor Y2 | Neuropeptide receptor binding in metabolism. |
| NTSR1 | Neurotensin receptor 1 | Neuropeptide receptor binding in dopamine signaling. |
| NTSR2 | Neurotensin receptor 2 | Neuropeptide receptor binding in pain modulation. |
| CCKAR | Cholecystokinin A receptor | Neuropeptide receptor binding in digestion and anxiety. |
How Is neuropeptide receptor binding Regulated?
Neuropeptide receptor binding is regulated at multiple levels. Receptor expression levels, post-translational modifications, and membrane lipid composition can influence binding affinity and kinetics. Allosteric modulators and competitive antagonists can directly interfere with the binding pocket, as shown for NPBWR1 and MRGPRX2. Additionally, genetic variants such as the I107 variant of NPSR1 alter binding and activation, demonstrating that sequence variation regulates this function. In pathophysiological states, chronic stress or inflammation can change neuropeptide release and receptor binding, as observed in high-anxiety rats with altered vasopressin receptor binding.
neuropeptide receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPSR1 | Anxiety disorders | Knock-in mouse expressing I107 variant; binding assays. |
| MRGPRX2 | Chronic itch, pseudo-allergy | Knockout mast cells; MRGPRX2 overexpression in HEK293. |
| AVPR1A | High anxiety | Rat model with altered vasopressin binding; KO rats. |
| GHRHR | Cancer | Xenograft models with receptor overexpression; KO cancer cells. |
| NPBWR1 | Metabolic and inflammatory conditions | Point-mutation knock-in mice; antagonist binding assays. |
Anxiety and stress-related disorders
Alterations in central neuropeptide expression, release, and receptor binding are observed in rats bred for high anxiety, with a critical role for vasopressin. The neuropeptide S receptor variant I107 has been studied for its binding properties and selective activation, linking it to anxiety-related phenotypes. These findings suggest that dysregulated neuropeptide receptor binding contributes to emotional dysregulation.
Allergic and pruritic diseases
Neuropeptide receptor binding on mast cells and sensory neurons is implicated in itch and allergic inflammation. MRGPRX2 binds neuropeptides and drugs, triggering mast cell activation and pruritus; inhibitors like KMH-45 block this binding and reduce itch. Structural studies of human itch receptor complexes have elucidated how neuropeptides engage these receptors, providing a basis for anti-pruritic drug design.
Cancer
Growth hormone-releasing hormone and its receptor binding are involved in cancer cell proliferation and survival. Antagonists that block GHRH receptor binding are being explored as anticancer agents. This highlights the broader oncogenic potential of neuropeptide receptor binding pathways.
From neuropeptide receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of receptor abolish neuropeptide binding? | Knockout cell line or animal (e.g., NPSR1 KO). |
| How does a specific variant alter binding affinity? | Point-mutation knock-in (e.g., NPSR1 I107). |
| Can a tagged receptor track binding dynamics? | Tagged knock-in (e.g., GFP-NPBWR1). |
| Does overexpression sensitize cells to neuropeptides? | Overexpression stable cell line (e.g., MRGPRX2). |
| Which genes modulate neuropeptide receptor binding? | CRISPR library screening in relevant cell types. |
| Does a disease-associated mutation affect binding? | Patient-derived iPSCs with isogenic point mutation. |
How to Study the neuropeptide receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity (KD), receptor density (Bmax) | Characterizing neuropeptide S receptor binding. |
| Surface plasmon resonance | Association and dissociation rates (kon, koff) | Kinetic profiling of neuropeptide-receptor interactions. |
| Cryo-EM | 3D structure of receptor-ligand complex | Visualizing itch receptor complexes with neuropeptides. |
| Site-directed mutagenesis | Effect of specific residues on binding | Mapping NPBWR1 antagonist binding pocket. |
| Molecular docking | Predicted binding poses and energies | Computational insights into antagonist binding. |
| CRISPR knockout | Loss-of-function effect on binding | Validating receptor necessity in cells. |
| CRISPR knock-in | Effect of disease variants on binding | Modeling NPSR1 I107 variant. |
| Overexpression | Gain-of-function binding capacity | Sensitizing cells to neuropeptides. |
Radioligand binding assays
Radioligand binding assays measure the affinity and kinetics of neuropeptide-receptor interactions using labeled ligands. These assays have been used to characterize neuropeptide S receptor binding and to identify suitable peptide tracers. They provide quantitative data on KD, Bmax, and competition with antagonists.
Surface plasmon resonance (SPR)
SPR measures real-time association and dissociation rates of neuropeptide-receptor binding without labels. It is valuable for determining kinetic constants (kon, koff) that define drug residence time. SPR has been applied to study neuropeptide-receptor interactions and to screen for allosteric modulators.
Structural biology (cryo-EM and X-ray crystallography)
Cryo-EM and X-ray crystallography provide atomic-level structures of neuropeptide receptors bound to ligands. Recent structures of human itch receptor complexes have revealed how neuropeptides and antagonists occupy the binding pocket. These structures guide rational drug design and mutagenesis studies.
Mutagenesis and computational modeling
Site-directed mutagenesis combined with molecular docking and dynamics simulations identifies residues critical for binding. Computational insights into antagonist binding with neuropeptide B/W receptor 1 have highlighted key interactions. Mutagenesis of neuropeptide S receptor identified residues important for binding and led to improved tracers.
How CRISPR Can Be Used to Study GO:0071855 neuropeptide receptor binding
Knockout
CRISPR knockout of a neuropeptide receptor gene eliminates binding and downstream signaling, providing a clean loss-of-function model. For example, knocking out NPSR1 or MRGPRX2 can confirm that observed binding is receptor-specific. Knockout models are essential for validating drug targets and for distinguishing receptor-mediated effects from off-target interactions.
Point Mutation
CRISPR point mutation introduces specific amino acid substitutions to test their impact on binding affinity and selectivity. The NPSR1 I107 variant has been modeled using point mutation to study altered binding and activation by selective peptides. Point mutations in the binding pocket of NPBWR1 can validate computational predictions of antagonist interactions.
Knock-in
CRISPR knock-in can insert tags (e.g., GFP, HA) or human disease variants into the endogenous receptor locus. Tagged knock-in allows real-time tracking of receptor localization and binding dynamics. Knock-in of disease-associated mutations, such as those in AVPR1A, can model altered binding in vivo.
Overexpression
CRISPR-mediated overexpression (e.g., via safe-harbor integration) increases receptor levels to enhance binding signals in assays. Overexpression of MRGPRX2 in mast cells or HEK293 cells has been used to study neuropeptide-induced activation and inhibitor efficacy. Overexpression models are useful for screening antagonists and for structural studies requiring high receptor yields.
How EDITGENE Supports neuropeptide receptor binding Research
Researchers studying neuropeptide receptor binding-related genes often need to determine whether a candidate receptor or ligand is causally involved in a specific biological process or disease. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support, enabling rigorous interrogation of GO:0071855 in any cell type.
Contact EDITGENE today to design your custom CRISPR model for neuropeptide receptor binding research.
Frequently Asked Questions About neuropeptide receptor binding
What is neuropeptide receptor binding?
Neuropeptide receptor binding (GO:0071855) is the molecular function of a ligand binding to a neuropeptide receptor, initiating signaling.
What genes are involved in neuropeptide receptor binding?
Key genes include NPSR1, NPBWR1, MRGPRX2, AVPR1A, and GHRHR, among others.
How is neuropeptide receptor binding measured?
It is measured using radioligand binding assays, surface plasmon resonance, and structural methods like cryo-EM.
What diseases are linked to neuropeptide receptor binding?
Anxiety, allergic itch, cancer, and stress-related disorders are linked to altered neuropeptide receptor binding.
What is the role of MRGPRX2 in neuropeptide receptor binding?
MRGPRX2 binds neuropeptides and drugs, triggering mast cell activation and itch; inhibitors like KMH-45 block this binding.
How do mutations affect neuropeptide receptor binding?
Mutations such as NPSR1 I107 can alter binding affinity and receptor activation, influencing disease susceptibility.
Can CRISPR be used to study neuropeptide receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are used to dissect binding mechanisms.
What is the kinetic profile of neuropeptide-receptor interactions?
It refers to association and dissociation rates that determine binding affinity and signaling duration.
Which neuropeptide receptors are targets for drug development?
NPSR1, NPBWR1, MRGPRX2, and GHRHR are among the targets being explored for therapeutic intervention.
How does vasopressin receptor binding relate to anxiety?
Altered vasopressin receptor binding in the brain is observed in high-anxiety rat models, suggesting a role in emotional regulation.
Conclusion
GO:0071855 neuropeptide receptor binding is a fundamental molecular function that governs neuropeptide signaling in health and disease. Its kinetic and structural properties determine the specificity and duration of cellular responses, with implications for anxiety, itch, allergy, and cancer. Advances in CRISPR-based models and structural biology are accelerating our understanding of this function and enabling the development of targeted therapeutics. EDITGENE provides the tools and expertise to interrogate neuropeptide receptor binding with precision, supporting researchers from target discovery to preclinical validation.
References
- 1. Nederpelt I et al.. 2016. Kinetic Profile of Neuropeptide-Receptor Interactions.. Trends Neurosci 39(12):830-839 PMID: 27793433
- 2. Patra MC et al.. 2014. Computational insights into the binding mechanism of antagonists with neuropeptide B/W receptor 1.. Mol Biosyst 10(8):2236-46 PMID: 24938207
- 3. Yang F et al.. 2021. Structure, function and pharmacology of human itch receptor complexes.. Nature 600(7887):164-169 PMID: 34789875
- 4. Treudler R et al.. 2023. Developments and perspectives in allergology.. J Dtsch Dermatol Ges 21(4):399-403 PMID: 37070510
- 5. Wigger A et al.. 2004. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin.. Neuropsychopharmacology 29(1):1-14 PMID: 12942143
- 6. Nepomuceno D et al.. 2010. Mutagenesis studies of neuropeptide S identify a suitable peptide tracer for neuropeptide S receptor binding studies and peptides selectively activating the I(107) variant of human neuropeptide S receptor.. Eur J Pharmacol 635(1-3):27-33 PMID: 20307531
- 7. Gesmundo I et al.. 2025. Growth hormone-releasing hormone and cancer.. Rev Endocr Metab Disord 26(3):443-456 PMID: 39422787
- 8. Sanjel B et al.. 2025. Identification of KMH-45, a novel MRGPRX2 inhibitor with enhanced anti-pruritic properties.. Biomed Pharmacother 190:118371 PMID: 40684495
